Shares skyrocket 30% on new trial data

Viking Therapeutics’ lead candidate VK2735 is one step closer to challenging the big guns in the weight loss space after a study showed that it remains effective on fortnightly or monthly maintenance doses, with rates of adverse gastrointestinal (GI) effects similar to placebo.

To see the whole article please log in.

Simon Webster

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here